Cowled P A, Forbes I J
Department of Medicine, University of Adelaide, Queen Elizabeth Hospital, Woodville, South Australia.
Br J Cancer. 1989 Jun;59(6):904-9. doi: 10.1038/bjc.1989.191.
Since the vascular endothelium is a primary site of damage after photodynamic therapy (PDT), it seemed likely that drugs which affect the vasculature may modify the outcome of PDT. Noradrenaline, propranolol, hydralazine and phenoxybenzamine inhibited photodynamic damage to tumours if these drugs were administered concurrently with HPD, 2 h before irradiation. This inhibition was associated with reduced uptake of HPD into tumours. There was no inhibition if irradiation was delayed until 24 h after administration of vasoactive drug, presumably because HPD uptake continued after the drugs had ceased to affect the vasculature. Verapamil enhanced photodynamic destruction of tumours when administered concurrently with HPD and the enhancement was associated with increased uptake of HPD into tumours. Verapamil neither increased uptake of HPD nor enhanced photodynamic destruction of cells in vitro. When verapamil was administered after irradiation, regrowth of tumours was inhibited. A similar effect was previously demonstrated with glucocorticoids. Other calcium channel blocking agents diltiazem and nifedipine had no effect on uptake of HPD or inhibition of regrowth of tumours after PDT. Inhibition of capillary or stromal ingrowth into tumours seems a plausible explanation of this effect of verapamil. This commonly used drug may be useful to enhance the efficacy of PDT.
由于血管内皮是光动力疗法(PDT)后主要的损伤部位,因此影响血管系统的药物似乎有可能改变PDT的治疗效果。如果在照射前2小时将去甲肾上腺素、普萘洛尔、肼屈嗪和酚苄明与血卟啉衍生物(HPD)同时给药,它们会抑制对肿瘤的光动力损伤。这种抑制作用与肿瘤对HPD摄取的减少有关。如果将照射推迟到血管活性药物给药后24小时进行,则不会出现抑制作用,推测是因为在药物不再影响血管系统后,HPD的摄取仍在继续。维拉帕米与HPD同时给药时可增强对肿瘤的光动力破坏作用,且这种增强作用与肿瘤对HPD摄取的增加有关。维拉帕米在体外既不会增加HPD的摄取,也不会增强对细胞的光动力破坏作用。当在照射后给予维拉帕米时,肿瘤的再生长会受到抑制。糖皮质激素之前也显示出类似的效果。其他钙通道阻滞剂地尔硫䓬和硝苯地平对PDT后HPD的摄取或肿瘤再生长的抑制没有影响。抑制毛细血管或基质向肿瘤内生长似乎是维拉帕米这种作用的一个合理的解释。这种常用药物可能有助于提高PDT的疗效。